ACE-031 is a recombinant fusion protein that acts as a myostatin inhibitor. Myostatin is a negative regulator of muscle growth, and by blocking its activity, ACE-031 promotes increased muscle mass and strength. It is primarily studied for its potential in treating muscle-wasting diseases and enhancing muscle development in both clinical and athletic settings.
Originally developed by Acceleron Pharma and Shire for the treatment of Duchenne muscular dystrophy (DMD), ACE-031 showed promise in increasing lean body mass.
Muscle Growth and Hypertrophy:
Purpose: Inhibits myostatin signaling to allow for uninhibited muscle growth.
Benefits: Increases lean muscle mass and improves strength.
Dosage Example: 1 mg subcutaneously twice weekly for 4-6 weeks.
Treatment of Muscle-Wasting Conditions:
Purpose: Preserves muscle tissue in catabolic states.
Benefits: Helps patients retain mobility and quality of life during illness.
Dosage Example: 1-2 mg subcutaneously weekly under supervision.
Athletic Recovery and Injury Support:
Purpose: Promotes recovery and muscular regeneration following injury or overtraining.
Benefits: Enhances tissue repair and maintains muscle volume.
Dosage Example: 1 mg subcutaneously 2x/week for 4 weeks post-injury.
Age-Related Sarcopenia:
Purpose: Addresses muscle loss associated with aging.
Benefits: Improves strength and functionality in older adults.
Dosage Example: 1 mg subcutaneous weekly for 8-12 weeks.
Support During Immobilization or Bedrest:
Purpose: Prevents disuse atrophy during periods of inactivity.
Benefits: Helps preserve muscle mass in orthopedic or postoperative patients.
Dosage Example: 1-2 mg subcutaneously weekly during recovery period.
SKU: MAF-ACE-1mg-SV-KIT
